Aimmune Therapeutics to Participate in Four Investor Conferences in March

BRISBANE, Calif.--()--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in March:

Event: 30th Annual ROTH Conference
Date: Monday, March 12, 2018
Presentation Time: 3:30 p.m. Pacific Time
Location: Laguna Niguel, CA
Presenter: Jeff Knapp, Chief Operating Officer, and Mary Rozenman, Ph.D., Senior Vice President, Corporate Development and Strategy

Event: Cowen and Company 38th Annual Health Care Conference
Date: Tuesday, March 13, 2018
Presentation Time: 8:00 a.m. Eastern Time
Location: Boston, MA
Presenter: CEO Stephen Dilly, M.B.B.S., Ph.D.

Event: Barclays Global Healthcare Conference
Date: Wednesday, March 14, 2018
Presentation Time: 11:15 a.m. Eastern Time
Location: Miami, FLA
Presenter: CEO Stephen Dilly, M.B.B.S., Ph.D.

Event: 17th Annual Needham Healthcare Conference
Date: Tuesday, March 27, 2018
Presentation Time: 4:30 p.m. Eastern Time
Location: New York, NY
Presenter: CEO Stephen Dilly, M.B.B.S., Ph.D.

Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays of the webcasts will be available for at least 30 days following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Contacts

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com

Recent Stories

RSS feed for Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.